|
|||||
|
|
Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates |
|
| Affiliation: | 1. Merck & Co., Inc., Kenilworth, NJ, USA;2. Vaxine Pty Ltd, Flinders University, Bedford Park SA 5042, Australia |
| Abstract: | |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |